



EACR 2026 Congress: Call for Abstracts

Abstract submission deadline: **04 March 2026**.

ABSTRACT REGULATIONS

By submitting an abstract to the Congress, the submitting author agrees to the following regulations. Please read them carefully, in full, before submitting an abstract.

Abstract Submission

- Abstracts can only be submitted online.
- **The presenting author must submit the abstract.** If necessary, the presenting author can be changed later by contacting us.
- The presenting author will be the only author to receive communications about the abstract.
- **A non-refundable abstract submission fee of €30 plus VAT per abstract applies to cover the administrative costs of processing and managing submissions.** This must be paid **by credit or debit card at the point of abstract submission** and cannot be refunded under any circumstances, including if the abstract is not accepted.
- Within 48 hours of submission we will email the presenting author a submission confirmation and abstract number. This confirmation is not a notice of acceptance to present at the Congress.
- **After you have submitted an abstract, NO further edits of any kind are possible.** It is therefore extremely important to **check abstract content, authors and affiliations carefully** before you submit, and ensure you have the relevant permissions to publish the data submitted.
- If the abstract is accepted, and **only if the presenting author is duly registered**, abstracts will be published on the Congress website and through the Congress app, and will also be published after the Congress in an online supplement to the journal *Molecular Oncology*.

Registration and Abstract Presentation

- All accepted abstracts must be presented in person.
- The presenting author agrees to register for the Congress and present in detail the research discussed in the abstract. **It is very important to register using the same website login** (with the same email address) that you used to submit the abstract.
- If the assigned presenter cannot attend the Congress, the authors should contact us to designate a replacement or withdraw the abstract no later than **21 April 2026**.

- **IMPORTANT:** If by **21 April 2026** the presenting author of the abstract has not registered, the abstract will be withdrawn from the Congress programme and any abstract publications, and no poster board will be provided.
- **Don't let a visa be the reason you miss out.** Delays in receiving a visa can cause authors to be unable to register, leading to abstracts being automatically withdrawn. We strongly advise that authors put funding and/or visa arrangements in place as early as possible to avoid disappointment. **If possible, we advise authors to apply for their visa as soon as their abstract is submitted.**

Abstract Content

With the submission of an abstract to the EACR 2026 Congress, the presenting author:

- Accepts responsibility for the accuracy of the submitted abstract.
- Confirms that all co-authors are aware of and agree to the content of the abstract and support the data presented.
- Confirms that all co-authors agree to the abstract's publication, if accepted, on the Congress website and app and in an online supplement to *Molecular Oncology*.
- Warrants that the text of the abstract has not been published previously with the same wording and title prior to the date of the Congress. The underlying research may have been published in another format (e.g. journal article, preprint), but to avoid copyright issues the abstract text itself must be original and not a verbatim reproduction.
- Uses the Acknowledgements section to identify any financial interest in products or processes described in the abstract. This information will be forwarded to the Scientific Committee together with the abstract.
- States that, for studies involving human or animal subjects, permission has been obtained from the relevant regulatory authority and properly informed consent given where appropriate.

Abstract Format

In order to be considered, an abstract should respect the following guidelines:

- The abstract must be submitted in good English. The Scientific Committee reserves the right to reject those abstracts which are presented in poor English, or may request an immediate revision by the presenter.
- Abstract titles should be brief and should reflect the content of the abstract.
- Commercial names may not be used in the abstract title.
- A maximum of 10 authors may be listed. If the work was carried out by a larger group, a Working Group or Consortium may be added as an 11th author. Additional contributors should be

mentioned in the Acknowledgements. As abstracts are short summaries rather than full scientific papers, more than 10 individual authors are not permitted.

- Abstracts should be organised under the headings:
 - Introduction
 - Material and method
 - Results and discussion
 - Conclusion
 - Acknowledgements
- The online abstract submission procedure will not accept abstracts that exceed 2,500 characters (body of the abstract; without spaces).
- Abbreviations may be used if standard or if spelled out and defined at the first use. Compounds should be mentioned with the generic name, in lower case. Commercial names are permitted in the text, with an ®, and if in brackets following the generic name, i.e. “generic (Commercial ®)”.
- Supplementary data or appendices **will not be accepted**.
- **Figures or photographs are not allowed**. Symbols and structures of drugs are allowed and should be included in the text itself.

Abstract Selection Process

- The Scientific Committee will make the selection of abstracts for oral and poster presentations by **01 April 2026**.
- The presenting author will receive an email with the result of the review and the Scientific Committee’s decision on the abstract no later than **01 April 2026**.
- Further instructions on how to prepare posters or presentations at the Congress will be provided.
- To ensure your abstract is not automatically withdrawn, please take note of the important information given in the **Registration and Abstract Presentation** section of this document.
- The following presentation formats are applicable for the EACR 2026 Congress:
 1. **Oral presentation:** the abstract is selected for oral presentation in a main Congress symposium
 2. **Poster:** abstracts that have been selected for presentation in a poster format. Posters are grouped by (main) topic and displayed during specific Poster Sessions. A formal Poster Discussion Session will be scheduled.
 3. **Poster Presentation with Poster in the Spotlight session:** in addition to a poster presentation as above, a **5-minute presentation** is delivered at a designated time **in the Posters in the Spotlight Session**, located in the poster and exhibition area.

Contact us

For questions regarding the online submission process, please contact: eacr@newway-management.com

TOPICS FOR ABSTRACT SUBMISSION

1. BIOINFORMATICS AND COMPUTATIONAL BIOLOGY

Application of Bioinformatics to Cancer Biology
Artificial Intelligence and Machine Learning
New Algorithms and new Software for Data Analysis
Omics Technologies
Digital Clinical Trials

2. BIOMARKERS IN TISSUE AND BLOOD

Liquid Biopsies: Circulating DNA
Liquid Biopsies: Circulating Tumour Cells
Diagnostic Biomarkers
Prognostic Biomarkers
Biomarkers Predictive of Therapeutic Benefit
Early Detection Biomarkers

3. CANCER CELL BIOLOGY

Cell Proliferation/Cell Cycle
Cell Death / Autophagy
Oncogenes and Tumour Suppressor Genes
Metastases and EMT
Aging and Cancer
Senescence
Cancer Cell Metabolism
Cancer Initiating Cells / Cancer Stem Cells

4. CANCER GENOMICS

Genomic Alterations in Cancer
Functional Genomics
Genomic profiling of Tumours
Spatial and 3D Analysis of Tumours
Genomes and Transcriptomes of Cancer at Single Cell Level

5. CARCINOGENESIS

Promotion and Progression
DNA Damage and Repair
Viral Oncogenesis

6. DRUG RESISTANCE

Novel Mechanisms
Regulation of Gene Expression in Drug Resistance
Reversal of Drug Resistance
Resistance to Immune Checkpoint Blockade and other Immune based Therapies

7. EPIGENETICS

DNA Methylation
Epigenetic changes as Molecular Markers of Cancer
Epigenetic Mechanisms and Gene Silencing

8. EXPERIMENTAL / MOLECULAR THERAPEUTICS, PHARMACOGENOMICS

Drug Discovery / Drug Design
Novel Targets, Delivery Systems
Mechanisms of Drug Action, Drug Profiling
New Therapies
Precision Medicine

9. IMMUNOTHERAPY

Adoptive Cell Therapy
Immune Response to Therapies
Immunomodulatory Agents and Interventions
Therapeutic Antibodies, including Engineered Antibodies
Vaccines
Immune Checkpoints
Immune Mechanisms invoked by other Therapies including CARs

10. MOLECULAR AND GENETIC EPIDEMIOLOGY

Epidemiology

11. PREVENTION and EARLY DETECTION

Preclinical Prevention Studies, Markers and Prevention
Clinical Prevention Studies
Risk Factors: Heritable and Lifestyle related Risk Factors

12. RADIOBIOLOGY / RADIATION ONCOLOGY

Tumour Cell Sensitisation to Radiotherapy
Radiation Oncology; Preclinical and Clinical
Translational Radiation Research

13. SIGNALING PATHWAYS

Receptors and Signal Transduction
Gene Expression, Transcriptional Regulation
Computational Models of Biological Systems

14. TRANSLATIONAL RESEARCH

Organ Site-Specific Investigations: Preclinical, Diagnosis, Treatment
Molecular Pathology
Imaging
Infrastructures (Biobanks, Databases, Genomic Resources, others)
Nanotechnologies in Cancer Research

15. TUMOUR BIOLOGY

Animal Models of Cancer

Genetic and Genomic Instability

Tumour Progression: Invasion and Metastasis

Tumour Microenvironment

RNA Biology in Cancer (splicing, noncoding RNAs, RNA modifications) and Therapy Response

Tumour Dormancy and Persister Cells

16. TUMOUR EVOLUTION AND HETEROGENEITY

Causes and Consequences of Tumour Heterogeneity

Methods to measure Tumour Evolution and Heterogeneity

Drug Resistance and Clonal Evolution

17. TUMOUR IMMUNOLOGY

Tumour Immunology

Immune Suppression and Escape

Microbiome and Cancer